GAM Holding AG Has $2.54 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

GAM Holding AG boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,033 shares of the company’s stock after acquiring an additional 140 shares during the quarter. GAM Holding AG’s holdings in IDEXX Laboratories were worth $2,543,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IDXX. Riverview Trust Co bought a new stake in shares of IDEXX Laboratories during the first quarter worth $26,000. Crewe Advisors LLC bought a new stake in shares of IDEXX Laboratories during the first quarter worth $26,000. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories during the second quarter worth $27,000. Institutional & Family Asset Management LLC bought a new stake in shares of IDEXX Laboratories during the second quarter worth $28,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories during the second quarter worth $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IDXX. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Finally, Piper Sandler cut their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Trading Up 1.8 %

NASDAQ IDXX opened at $461.49 on Wednesday. The firm has a market cap of $38.11 billion, a P/E ratio of 44.67, a P/E/G ratio of 4.14 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The stock’s 50-day moving average is $486.45 and its 200-day moving average is $490.46. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.67 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.